Medical and veterinary adhesives and sealants are used in clinics and surgery as an alternative to other wound closure methods such as sutures or staples. In addition, they allow wounds to stop bleeding quickly in accidents and health emergencies, shorten the healing time and minimize or completely eliminate scarring.
Currently, adhesives are based on synthetic or natural polymers. However, both kinds of polymers, present serious disadvantages. To overcome them, a Spanish research group has developed a new biomaterial for use as an adhesive or tissue sealant that has excellent properties such as biocompatibility with living tissues, high adhesive capacity, is adaptable to the tissue that is being bonded, has an absence of toxicity and tissue regeneration properties.
The polymeric biomaterial is preferably generated in situ on the wound to be closed, adding simultaneously on it a solution of a dendron (see Figure 1) and a cyanoacrylate adhesive. Then, in contact with body water or blood, the polymerization reaction of the cyanoacrylate is produced which chemically anchors dendron molecules, forming the corresponding polymeric biomaterial on the wound to be closed or sealed. The polymeric biomaterial hardens (curing process) as the polymerization reaction takes place, leaving a thin layer of it on the wound or tissue.
This invention can be very useful in the treatment and care of wounds, in the closing of wounds by accident, in medical, cosmetic and plastic surgeries, repair broken nails, etc.
The research group is looking for biomedical/pharmaceutical and veterinary companies interested in acquiring this technology for commercial exploitation through licensing agreements.
The research group would be also interested in establishing technical cooperation agreements to further develop this technology, to find new applications or to adapt it to the company’s needs. The University would offer its support based on their know-how; while, the partner sought would provide its expertise to help improve this invention. The university would offer this partner a preferential option to acquire this technology in exclusivity.